For example, empagliflozin reduced the incidence of AKI, while patients treated with canagliflozin and dapagliflozin developed AKI and even required hospitalization and dialysis, which may have been related to the differences in chemical structure and pharmacology of different SGLT2 inhibitors [89]. The gene discussed is SLC5A2; the disease is acute kidney injury.